ReviewPathogens (Basel, Switzerland)2022
Antiviral Agents against Flavivirus Protease: Prospect and Future Direction.
Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Targeting a genomic RNA G-quadruplex of dengue virus with small molecules as an alternative to protein-targeted therapeutics.Journal of biomedical science · 2026Article
- mbioRxiv : the preprint server for biology · 2026Article
- NUP98 regulates orthoflavivirus replication through interaction with vRNA and can be targeted for antiviral purposes.Nucleic acids research · 2026Article
- Development of Lipopeptides as Orthoflavivirin Inhibitors with Low Micromolar Broad-Spectrum Antiorthoflaviviral Activity.Journal of medicinal chemistry · 2025Article
- Article
- Dengue Virus Inhibitors as Potential Broad-Spectrum Flavivirus Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- The Role of Epigallocatechin Gallate (EGCG) in Treatment and Management of Sexually Transmitted Viral Infections.Infectious disorders drug targets · 2025Review
- Proteases: Role in Various Human Diseases.Current pharmaceutical biotechnology · 2025Review
- Identifying Allosteric Small-Molecule Binding Sites of Inactive NS2B-NS3 Proteases of PathogenicViruses · 2024Article
- Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition.Molecules (Basel, Switzerland) · 2024Review
- The Flavivirus Non-Structural Protein 5 (NS5): Structure, Functions, and Targeting for Development of Vaccines and Therapeutics.Vaccines · 2024Review
- Dengue virus non-structural protein 3 inhibits mitochondrial respiration by impairing complex I function.mSphere · 2024Article
- Implementation of IFPTML Computational Models in Drug Discovery Against Flaviviridae Family.Journal of chemical information and modeling · 2024Article
- Reverse Genetics of Zika Virus Using a Bacterial Artificial Chromosome.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Utility of an In-Vitro Micro-Neutralizing Test in Comparison to a Plaque Reduction Neutralization Test for Dengue Virus, Japanese Encephalitis Virus, and Zika Virus Serology and Drug Screening.Pathogens (Basel, Switzerland) · 2023Article
- Acetylation of the NS3 helicase by KAT5γ is essential for flavivirus replication.Cell host & microbe · 2023Article
- Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).European journal of medicinal chemistry · 2023Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Flaviviruses cause a significant amount of mortality and morbidity, especially in regions where they are endemic. A recent example is the outbreak of Zika virus throughout the world. Development of antiviral drugs against different viral targets is as important as the development of vaccines. During viral replication, a single polyprotein precursor (PP) is produced and further cleaved into individual proteins by a viral NS2B-NS3 protease complex together with host proteases. Flavivirus protease is one of the most attractive targets for development of therapeutic antivirals because it is essential for viral PP processing, leading to active viral proteins. In this review, we have summarized recent development in drug discovery targeting the NS2B-NS3 protease of flaviviruses, especially Zika, dengue, and West Nile viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.